What does this research mean for the field?

In Peruvian patients with breast and ovarian cancer, pathogenic BRCA1/2 variants are associated with a higher risk of developing second primary malignancies, particularly new breast cancer, and BRCA1 mutations correlate with a higher incidence of triple-negative tumors. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to describe the clinical and genomic characteristics of patients with breast and ovarian cancer who underwent BRCA1/2 testing in Peru.

February 22, 2026Clinical Cancer Research

Abstract PS3-03-22: Brca1/2-tested breast and ovarian cancer patients in peru: clinical and genomic features

View Full Paper

Ask AI

Bookmark

Authors

PMPamela Mora NVNI Valdiviezo MAMarisa Acosta

Discussion

Member takes

Overview

Study reveals clinical and genomic insights about breast and ovarian cancer in Peru, indicating a need for enhanced genetic services.

Key Points

This research aims to describe the clinical and genomic characteristics of patients with breast and ovarian cancer who underwent BRCA1/2 testing in Peru.
Included patients diagnosed with breast and/or ovarian cancer at a genetic evaluation center.
Utilized univariate and multivariate Cox regression for overall survival analysis.
Examined diagnostic data from August 2013 to March 2020.
1,576 patients studied, with a median diagnosis age of 41 years and 99.3% female.
BRCA1 pathogenic variants found in 7.2% and BRCA2 in 3.2% of the population.
Triple-negative subtype observed in 85.4% of BRCA1-positive breast tumors.
Advanced clinical stage and certain tumor subtypes linked to poorer overall survival.
15% developed a second primary malignancy, most commonly a new breast cancer.

Cite This Study

Mora et al. (2026) studied this question.

synapsesocial.com/papers/699a9e20482488d673cd48c7 https://doi.org/10.1158/1557-3265.sabcs25-ps3-03-22

View Full Paper

Ask AI

Bookmark

February 22, 2026Clinical Cancer Research

Abstract PS3-03-22: Brca1/2-tested breast and ovarian cancer patients in peru: clinical and genomic features

View Full Paper

Ask AI

Bookmark

Authors

PMPamela Mora NVNI Valdiviezo MAMarisa Acosta

Discussion

Member takes

Overview

Study reveals clinical and genomic insights about breast and ovarian cancer in Peru, indicating a need for enhanced genetic services.

Key Points

This research aims to describe the clinical and genomic characteristics of patients with breast and ovarian cancer who underwent BRCA1/2 testing in Peru.
Included patients diagnosed with breast and/or ovarian cancer at a genetic evaluation center.
Utilized univariate and multivariate Cox regression for overall survival analysis.
Examined diagnostic data from August 2013 to March 2020.
1,576 patients studied, with a median diagnosis age of 41 years and 99.3% female.
BRCA1 pathogenic variants found in 7.2% and BRCA2 in 3.2% of the population.
Triple-negative subtype observed in 85.4% of BRCA1-positive breast tumors.
Advanced clinical stage and certain tumor subtypes linked to poorer overall survival.
15% developed a second primary malignancy, most commonly a new breast cancer.

Cite This Study

Mora et al. (2026) studied this question.

synapsesocial.com/papers/699a9e20482488d673cd48c7 https://doi.org/10.1158/1557-3265.sabcs25-ps3-03-22

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark